Univariate regression models of entire study cohort
| . | Relapse . | RFS . | OS . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Pre-HCT MRD status | ||||||||
| MRDneg (n = 649) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos (n = 161) | 4.31 (3.37-5.52) | <.001 | 3.28 (2.66-4.04) | <.001 | 2.67 (2.15-3.32) | <.001 | 1.71 (1.12-2.62) | .014 |
| Early post-HCT MRD status | ||||||||
| MRDneg (n = 749) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos (n = 61) | 10.96 (8.06-14.91) | <.001 | 8.10 (6.11-10.74) | <.001 | 3.90 (2.92-5.21) | <.001 | 2.18 (0.89-5.35) | .089 |
| Early peri-HCT MRD dynamics | ||||||||
| MRDneg/MRDneg (n = 631) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDneg/MRDpos (n = 18) | — | — | — | — | 6.24 (3.80-10.25) | <.001 | — | — |
| MRDpos/MRDneg (n = 118) | 3.93 (2.95-5.24) | <.001 | 2.91 (2.29-3.70) | <.001 | 2.48 (1.93-3.19) | <.001 | 1.60 (1.01-2.55) | .046 |
| MRDpos/MRDpos (n = 43) | 11.15 (7.70-16.15) | <.001 | 7.58 (5.44-10.57) | <.001 | 4.18 (2.96-5.89) | <.001 | 2.37 (0.96-5.85) | .06 |
| Quantitative MRD dynamics | ||||||||
| MRDneg (n = 631) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDdecreasing (n = 143) | 4.46 (3.42-5.82) | <.001 | 3.23 (2.59-4.03) | <.001 | 2.56 (2.03-3.23) | <.001 | 1.63 (1.05-2.53) | .13 |
| MRDstable/increasing (n = 36) | 29.64 (19.84-44.26) | <.001 | 20.79 (14.36-30.12) | <.001 | 7.17 (4.99-10.30) | <.001 | 4.09 (0.99-16.87) | .051 |
| Post-HCT PB CD3 chimerism | ||||||||
| Full (n = 335) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Mixed (n = 230) | 1.40 (1.06-1.85) | .019 | 1.27 (1.02-1.59) | .037 | 1.11 (0.87-1.40) | .53 | 1.07 (0.73-1.56) | .74 |
| Conditioning regimen | ||||||||
| MAC (n = 515) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Non-MAC (n = 295) | 1.50 (1.18-1.91) | .0011 | 1.81 (1.49-2.20) | <.001 | 1.76 (1.43-2.15) | <.001 | 2.54 (1.84-3.51) | <.001 |
| Disease status | ||||||||
| First remission (n = 617) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Second remission (n = 193) | 1.36 (1.04-1.78) | .024 | 1.41 (1.14-1.75) | .0015 | 1.50 (1.20-1.87) | <.001 | 1.52 (1.06-2.16) | .021 |
| Cytogenetic risk | ||||||||
| Favorable/intermediate (n = 577) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Adverse (n = 200) | 2.05 (1.60-2.64) | <.001 | 1.42 (1.15-1.76) | .0013 | 1.27 (1.01-1.59) | .041 | 0.58 (0.36-0.92) | .02 |
| Age at HCT (per 10 y) | 1.09 (1.00-1.19) | .061 | 1.20 (1.11-1.29) | <.001 | 1.20 (1.11-1.30) | <.001 | 1.47 (1.29-1.69) | <.001 |
| WBC at diagnosis | 1.00 (1.00-1.00) | .76 | 1.00 (1.00-1.00) | .24 | 1.00 (1.00-1.00) | .12 | 1.00 (1.00-1.00) | .77 |
| HCT comorbidity index | ||||||||
| 0-1 (n = 241) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| 2-3 (n = 316) | 1.06 (0.79-1.41) | .71 | 1.16 (0.92-1.48) | .21 | 1.21 (0.94-1.56) | .14 | 1.41 (0.93-2.14) | .10 |
| ≥4 (n = 253) | 1.15 (0.85-1.56) | .37 | 1.34 (1.05-1.71) | .021 | 1.40 (1.08-1.82) | .01 | 1.78 (1.17-2.72) | .0077 |
| Type of AML | ||||||||
| De novo (n = 592) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Secondary (n = 218) | 1.17 (0.90-1.52) | .24 | 1.27 (1.03-1.56) | .025 | 1.25 (1.01-1.56) | .043 | 1.45 (1.03-2.03) | .032 |
| Pre-HCT karyotype | ||||||||
| Normalized (n = 319) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not normalized (n = 128) | 2.27 (1.66-3.10) | <.001 | 2.19 (1.69-2.85) | <.001 | 2.05 (1.55-2.71) | <.001 | 1.96 (1.20-3.20) | .0069 |
| Pre-HCT blood counts* | ||||||||
| Recovered (n = 589) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not recovered (n = 221) | 1.09 (0.84-1.43) | .52 | 1.31 (1.07-1.62) | .01 | 1.38 (1.11-1.72) | .0035 | 1.80 (1.20-2.52) | <.001 |
| Stem cell source | ||||||||
| PB (n = 628) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| BM (n = 69) | 1.26 (0.85-1.86) | .25 | 1.00 (0.71-1.41) | .99 | 1.00 (0.70-1.42) | .98 | 0.58 (0.28-1.18) | .25 |
| UCB (n = 113) | 0.83 (0.57-1.21) | .33 | 0.89 (0.66-1.19) | .42 | 0.96 (0.71-1.30) | .80 | 0.98 (0.62-1.56) | .33 |
| . | Relapse . | RFS . | OS . | NRM . | ||||
|---|---|---|---|---|---|---|---|---|
| . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Pre-HCT MRD status | ||||||||
| MRDneg (n = 649) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos (n = 161) | 4.31 (3.37-5.52) | <.001 | 3.28 (2.66-4.04) | <.001 | 2.67 (2.15-3.32) | <.001 | 1.71 (1.12-2.62) | .014 |
| Early post-HCT MRD status | ||||||||
| MRDneg (n = 749) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDpos (n = 61) | 10.96 (8.06-14.91) | <.001 | 8.10 (6.11-10.74) | <.001 | 3.90 (2.92-5.21) | <.001 | 2.18 (0.89-5.35) | .089 |
| Early peri-HCT MRD dynamics | ||||||||
| MRDneg/MRDneg (n = 631) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDneg/MRDpos (n = 18) | — | — | — | — | 6.24 (3.80-10.25) | <.001 | — | — |
| MRDpos/MRDneg (n = 118) | 3.93 (2.95-5.24) | <.001 | 2.91 (2.29-3.70) | <.001 | 2.48 (1.93-3.19) | <.001 | 1.60 (1.01-2.55) | .046 |
| MRDpos/MRDpos (n = 43) | 11.15 (7.70-16.15) | <.001 | 7.58 (5.44-10.57) | <.001 | 4.18 (2.96-5.89) | <.001 | 2.37 (0.96-5.85) | .06 |
| Quantitative MRD dynamics | ||||||||
| MRDneg (n = 631) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| MRDdecreasing (n = 143) | 4.46 (3.42-5.82) | <.001 | 3.23 (2.59-4.03) | <.001 | 2.56 (2.03-3.23) | <.001 | 1.63 (1.05-2.53) | .13 |
| MRDstable/increasing (n = 36) | 29.64 (19.84-44.26) | <.001 | 20.79 (14.36-30.12) | <.001 | 7.17 (4.99-10.30) | <.001 | 4.09 (0.99-16.87) | .051 |
| Post-HCT PB CD3 chimerism | ||||||||
| Full (n = 335) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Mixed (n = 230) | 1.40 (1.06-1.85) | .019 | 1.27 (1.02-1.59) | .037 | 1.11 (0.87-1.40) | .53 | 1.07 (0.73-1.56) | .74 |
| Conditioning regimen | ||||||||
| MAC (n = 515) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Non-MAC (n = 295) | 1.50 (1.18-1.91) | .0011 | 1.81 (1.49-2.20) | <.001 | 1.76 (1.43-2.15) | <.001 | 2.54 (1.84-3.51) | <.001 |
| Disease status | ||||||||
| First remission (n = 617) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Second remission (n = 193) | 1.36 (1.04-1.78) | .024 | 1.41 (1.14-1.75) | .0015 | 1.50 (1.20-1.87) | <.001 | 1.52 (1.06-2.16) | .021 |
| Cytogenetic risk | ||||||||
| Favorable/intermediate (n = 577) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Adverse (n = 200) | 2.05 (1.60-2.64) | <.001 | 1.42 (1.15-1.76) | .0013 | 1.27 (1.01-1.59) | .041 | 0.58 (0.36-0.92) | .02 |
| Age at HCT (per 10 y) | 1.09 (1.00-1.19) | .061 | 1.20 (1.11-1.29) | <.001 | 1.20 (1.11-1.30) | <.001 | 1.47 (1.29-1.69) | <.001 |
| WBC at diagnosis | 1.00 (1.00-1.00) | .76 | 1.00 (1.00-1.00) | .24 | 1.00 (1.00-1.00) | .12 | 1.00 (1.00-1.00) | .77 |
| HCT comorbidity index | ||||||||
| 0-1 (n = 241) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| 2-3 (n = 316) | 1.06 (0.79-1.41) | .71 | 1.16 (0.92-1.48) | .21 | 1.21 (0.94-1.56) | .14 | 1.41 (0.93-2.14) | .10 |
| ≥4 (n = 253) | 1.15 (0.85-1.56) | .37 | 1.34 (1.05-1.71) | .021 | 1.40 (1.08-1.82) | .01 | 1.78 (1.17-2.72) | .0077 |
| Type of AML | ||||||||
| De novo (n = 592) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Secondary (n = 218) | 1.17 (0.90-1.52) | .24 | 1.27 (1.03-1.56) | .025 | 1.25 (1.01-1.56) | .043 | 1.45 (1.03-2.03) | .032 |
| Pre-HCT karyotype | ||||||||
| Normalized (n = 319) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not normalized (n = 128) | 2.27 (1.66-3.10) | <.001 | 2.19 (1.69-2.85) | <.001 | 2.05 (1.55-2.71) | <.001 | 1.96 (1.20-3.20) | .0069 |
| Pre-HCT blood counts* | ||||||||
| Recovered (n = 589) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| Not recovered (n = 221) | 1.09 (0.84-1.43) | .52 | 1.31 (1.07-1.62) | .01 | 1.38 (1.11-1.72) | .0035 | 1.80 (1.20-2.52) | <.001 |
| Stem cell source | ||||||||
| PB (n = 628) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | ||||
| BM (n = 69) | 1.26 (0.85-1.86) | .25 | 1.00 (0.71-1.41) | .99 | 1.00 (0.70-1.42) | .98 | 0.58 (0.28-1.18) | .25 |
| UCB (n = 113) | 0.83 (0.57-1.21) | .33 | 0.89 (0.66-1.19) | .42 | 0.96 (0.71-1.30) | .80 | 0.98 (0.62-1.56) | .33 |
ANC, absolute neutrophil count; BM, bone marrow; CI, confidence interval; HR, hazard ratio; PB, peripheral blood; UCB, umbilical cord blood.
Recovered: ANC ≥ 1000/µL and platelets ≥ 100 000/µL; not recovered: ANC < 1000/µL and/or platelets < 100 000/µL.